AnaptysBio (NASDAQ:ANAB) has been given a $63.00 price target by equities research analysts at Stifel Nicolaus in a report released on Monday, TipRanks reports. The firm presently has a “hold” rating on the biotechnology company’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 22.43% from the company’s current price.
Other equities analysts have also recently issued reports about the company. Credit Suisse Group lowered their price objective on AnaptysBio from $79.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, August 9th. HC Wainwright set a $126.00 price objective on shares of AnaptysBio and gave the stock a “buy” rating in a research report on Monday, June 24th. Zacks Investment Research downgraded shares of AnaptysBio from a “hold” rating to a “sell” rating in a research report on Monday, August 5th. Finally, SunTrust Banks decreased their price objective on shares of AnaptysBio from $125.00 to $93.00 and set a “buy” rating for the company in a research report on Monday, June 24th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $111.50.
ANAB stock traded up $2.47 during midday trading on Monday, hitting $51.46. The company’s stock had a trading volume of 400,515 shares, compared to its average volume of 269,259. The stock has a market capitalization of $1.32 billion, a P/E ratio of -20.51 and a beta of 1.37. AnaptysBio has a 12 month low of $46.03 and a 12 month high of $110.00. The business has a 50-day simple moving average of $53.91.
AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. The business had revenue of $5.00 million during the quarter. The company’s quarterly revenue was up 4900.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.57) earnings per share. As a group, equities analysts predict that AnaptysBio will post -3.76 EPS for the current year.
In related news, CEO Hamza Suria sold 22,428 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $73.76, for a total value of $1,654,289.28. Following the transaction, the chief executive officer now owns 31,524 shares in the company, valued at $2,325,210.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Marco Londei sold 10,060 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $73.06, for a total value of $734,983.60. Following the completion of the transaction, the insider now owns 32,437 shares in the company, valued at approximately $2,369,847.22. The disclosure for this sale can be found here. 14.00% of the stock is currently owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the stock. Aperio Group LLC bought a new position in AnaptysBio in the second quarter worth $45,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in AnaptysBio by 30.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,298 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 306 shares during the period. Amundi Pioneer Asset Management Inc. bought a new position in AnaptysBio in the first quarter worth $110,000. Bank of Montreal Can bought a new position in AnaptysBio in the second quarter worth $115,000. Finally, Whittier Trust Co. bought a new position in AnaptysBio in the second quarter worth $213,000.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
See Also: Percentage Gainers
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.